Nature Reviews. Drug Discovery最新文献

筛选
英文 中文
Design, simulate, refine: simulation-guided clinical trials for accelerated drug development 设计,模拟,完善:模拟指导临床试验,加速药物开发
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-13 DOI: 10.1038/s41573-026-01481-9
Elias Laurin Meyer, Tim Friede, Andrew P. Grieve, Christopher Jennison, Michael Krams, Elizabeth Lorenzi, Husseini K. Manji, Tobias Mielke, Jessica R. Overbey, Kert Viele, Marc K. Walton, Franz König
{"title":"Design, simulate, refine: simulation-guided clinical trials for accelerated drug development","authors":"Elias Laurin Meyer, Tim Friede, Andrew P. Grieve, Christopher Jennison, Michael Krams, Elizabeth Lorenzi, Husseini K. Manji, Tobias Mielke, Jessica R. Overbey, Kert Viele, Marc K. Walton, Franz König","doi":"10.1038/s41573-026-01481-9","DOIUrl":"10.1038/s41573-026-01481-9","url":null,"abstract":"Modern clinical trials are embracing innovative strategies including adaptive designs, biomarker-guided enrolment, master protocols and real-time decision-making. These approaches may accelerate discovery and improve outcomes, yet they also introduce additional complexity in study conduct and understanding of the design. Simulation-guided design can be a powerful tool for identifying the optimal design to address research questions and for understanding and communicating how the design functions in practice. Simulations can evaluate the operating characteristics of complex trials, including control of type I error and false discovery rate, power for sample size determination, and probabilities of adaptive decisions at interim analyses. Examining individual simulated trials alongside these summaries provides insight into how the design will perform in practice, allowing potential risks to be anticipated and the design refined. Here, we outline how trial simulation can empower clinical development teams, statisticians, data monitoring committees, regulators, sponsors, funders and patient advocates by improving cross-functional communication, enhancing understanding and providing objective justification for design choices. We also provide best-practice recommendations to ensure that simulation studies are valid, transparent, thorough, efficient and comparable — helping to create trial designs that are scientifically rigorous, ethically sound, operationally practical and ultimately capable of bringing safe and effective therapies to patients as efficiently as possible. Simulation-guided clinical trial design can enable identification of the optimal design to bring safe and effective therapies to patients as efficiently as possible, and it is particularly useful when exploring innovative strategies such as adaptive designs and master protocols. This Perspective discusses the value of trial simulations from the perspective of different stakeholders involved in drug development, presents best-practice recommendations, and highlights case studies that illustrate the impact of the approach.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 10","pages":"792-808"},"PeriodicalIF":91.2,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148432029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA new drug approvals in Q2 2026 2026年第二季度FDA新药批准。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-10 DOI: 10.1038/d41573-026-00120-7
Paul Verdin
{"title":"FDA new drug approvals in Q2 2026","authors":"Paul Verdin","doi":"10.1038/d41573-026-00120-7","DOIUrl":"10.1038/d41573-026-00120-7","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"585-585"},"PeriodicalIF":91.2,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing challenges in treating rare tumours: the strategy of China’s National Cancer Center 应对罕见肿瘤治疗的挑战:中国国家癌症中心的战略。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-09 DOI: 10.1038/s41573-026-01484-6
Shuhang Wang, Jiawei Zhou, Hanqing He, Peiwen Ma, Yale Jiang, Ning Li
{"title":"Addressing challenges in treating rare tumours: the strategy of China’s National Cancer Center","authors":"Shuhang Wang, Jiawei Zhou, Hanqing He, Peiwen Ma, Yale Jiang, Ning Li","doi":"10.1038/s41573-026-01484-6","DOIUrl":"10.1038/s41573-026-01484-6","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 9","pages":"739-740"},"PeriodicalIF":91.2,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148416336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA approves novel cell therapy made with haematopoietic stem cells, Tregs and T cells FDA批准由造血干细胞、Tregs和T细胞制成的新型细胞疗法。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-08 DOI: 10.1038/d41573-026-00119-0
Asher Mullard
{"title":"FDA approves novel cell therapy made with haematopoietic stem cells, Tregs and T cells","authors":"Asher Mullard","doi":"10.1038/d41573-026-00119-0","DOIUrl":"10.1038/d41573-026-00119-0","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"584-584"},"PeriodicalIF":91.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148408440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T cell therapy for solid cancer scores first approval in China CAR - T细胞治疗实体癌在中国首次获批。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-08 DOI: 10.1038/d41573-026-00117-2
Asher Mullard
{"title":"CAR T cell therapy for solid cancer scores first approval in China","authors":"Asher Mullard","doi":"10.1038/d41573-026-00117-2","DOIUrl":"10.1038/d41573-026-00117-2","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"583-583"},"PeriodicalIF":91.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148408400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA approves second IGF-1R-targeted antibody for thyroid eye disease FDA批准第二种igf - 1r靶向抗体治疗甲状腺眼病。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-08 DOI: 10.1038/d41573-026-00118-1
Asher Mullard
{"title":"FDA approves second IGF-1R-targeted antibody for thyroid eye disease","authors":"Asher Mullard","doi":"10.1038/d41573-026-00118-1","DOIUrl":"10.1038/d41573-026-00118-1","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"583-583"},"PeriodicalIF":91.2,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148408401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HuR degrader knocks down BRAF in cancer 在癌症中,HuR降解器可以降低BRAF。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-06 DOI: 10.1038/d41573-026-00116-3
Alex Eccleston
{"title":"HuR degrader knocks down BRAF in cancer","authors":"Alex Eccleston","doi":"10.1038/d41573-026-00116-3","DOIUrl":"10.1038/d41573-026-00116-3","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"590-590"},"PeriodicalIF":91.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
R&D productivity trends for biopharma companies in Asia and emerging markets 亚洲及新兴市场生物制药公司的研发生产力趋势。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-01 DOI: 10.1038/d41573-026-00114-5
Ajay Gautam
{"title":"R&D productivity trends for biopharma companies in Asia and emerging markets","authors":"Ajay Gautam","doi":"10.1038/d41573-026-00114-5","DOIUrl":"10.1038/d41573-026-00114-5","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 9","pages":"672-673"},"PeriodicalIF":91.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148365392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth in clinical research capability in China and impact on the pharmaceutical sector 中国临床研究能力的增长及其对制药行业的影响。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-01 DOI: 10.1038/d41573-026-00113-6
Huimin Guo,  Mengze Ruan,  Kenneth Kaitin,  Liming Shao
{"title":"Growth in clinical research capability in China and impact on the pharmaceutical sector","authors":"Huimin Guo, \u0000 Mengze Ruan, \u0000 Kenneth Kaitin, \u0000 Liming Shao","doi":"10.1038/d41573-026-00113-6","DOIUrl":"10.1038/d41573-026-00113-6","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"586-587"},"PeriodicalIF":91.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148365463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circular RNA guides exon skipping in DMD 环状RNA引导DMD外显子跳跃。
IF 91.2 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2026-07-01 DOI: 10.1038/d41573-026-00115-4
M. Teresa Villanueva
{"title":"Circular RNA guides exon skipping in DMD","authors":"M. Teresa Villanueva","doi":"10.1038/d41573-026-00115-4","DOIUrl":"10.1038/d41573-026-00115-4","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"25 8","pages":"592-592"},"PeriodicalIF":91.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148365391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书